<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Wowchemy 5.3.0 for Hugo"><link rel=preconnect href=https://fonts.gstatic.com crossorigin><link rel=preload as=style href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap"><link rel=stylesheet href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media=print onload='this.media="all"'><meta name=author content="Ali Emami"><meta name=description content="The artificial pancreas (AP) in its 2 versions, single-hormone AP (insulin only; SAP) and dual-hormone AP (insulin and glucagon; DAP), is a promising modality for the treatment of type 1 diabetes (T1D). We conducted an open-label, randomized, crossover study comparing SAP and DAP in 17 adults (age of 37.2±13.6 years, HBA1c 8.0±1.0%, during 2 types of exercises reported to have different hypoglycemic risks: moderate-intensity continuous exercise (60% VO2peak for 60 min) and high-intensity interval exercise (2 min alternating intervals at 85% and 50% VO2peak for 40 min, with 2×10 min at 45% VO2peak at the start and the end of the sessions). SAP and DAP were applied from 15:30 till 19:30, exercise started at 18:00 and announced 20 minutes earlier to the AP systems. During SAP as compared to DAP: exercise-induced hypoglycemia (plasma glucose ≤3.3 mmol/L with symptoms or <3 regardless of symptoms) was observed in 31.25% (10/32) vs. 9% (3/33) of interventions (p=0.02); the median (IQR) percentage of time with glucose <4.0 mmol/L was 11 (0 to 46.7)% vs. 0 (0 to 0)% (p=0.0001); time with glucose between 4 and 10 mmol/L was 71.4 (53.2 to 100)% vs. 100 (100 to 100)% (p=0.003); the median area under the curve for glucose <4.0 mmol/L was 31.6 (0 to 153.9 vs. 0 (0 to 0) mmol/L×min per h (p=0.0001). Higher doses of glucagon were needed during the continuous exercise 14.4 (9.5 to 16.9) mg vs. the interval exercise sessions 8.5 (4.6 to 16.9) mg (p=0.03). In summary, DAP is offering a tighter control and a better potential to prevent hypoglycemia during exercise in adults with T1D."><link rel=alternate hreflang=en-us href=https://aemami.ca/publication/taleb-2015-efficacy/><meta name=theme-color content="#4caf50"><script src=../../js/mathjax-config.js></script>
<link rel=stylesheet href=../../css/vendor-bundle.min.f1ecf783c14edc00c9320c205831ad8e.css media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/academicons@1.9.1/css/academicons.min.css integrity="sha512-W0xM4mr6dEP9nREo7Z9z+9X70wytKvMGeDsj7ps2+xg5QPrEBXC8tAW1IFnzjR6eoJ90JmCnFzerQJTLzIEHjA==" crossorigin=anonymous media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/styles/github.min.css crossorigin=anonymous title=hl-light media=print onload='this.media="all"'><link rel=stylesheet href=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/styles/dracula.min.css crossorigin=anonymous title=hl-dark media=print onload='this.media="all"' disabled><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.css integrity crossorigin=anonymous media=print onload='this.media="all"'><script src=https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js integrity crossorigin=anonymous async></script>
<link rel=stylesheet href=../../css/wowchemy.5d3041d0ccc87859ef36690573053291.css><link rel=manifest href=../../manifest.webmanifest><link rel=icon type=image/png href=../../media/icon_hu29bb0f8250f761abddc65535b755b381_104744_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=../../media/icon_hu29bb0f8250f761abddc65535b755b381_104744_180x180_fill_lanczos_center_3.png><link rel=canonical href=https://aemami.ca/publication/taleb-2015-efficacy/><meta property="twitter:card" content="summary"><meta property="og:site_name" content="Ali Emami"><meta property="og:url" content="https://aemami.ca/publication/taleb-2015-efficacy/"><meta property="og:title" content="The efficacy of single-and dual-hormone artificial pancreas systems at regulating glucose levels during continuous and interval exercise in type 1 diabetes | Ali Emami"><meta property="og:description" content="The artificial pancreas (AP) in its 2 versions, single-hormone AP (insulin only; SAP) and dual-hormone AP (insulin and glucagon; DAP), is a promising modality for the treatment of type 1 diabetes (T1D). We conducted an open-label, randomized, crossover study comparing SAP and DAP in 17 adults (age of 37.2±13.6 years, HBA1c 8.0±1.0%, during 2 types of exercises reported to have different hypoglycemic risks: moderate-intensity continuous exercise (60% VO2peak for 60 min) and high-intensity interval exercise (2 min alternating intervals at 85% and 50% VO2peak for 40 min, with 2×10 min at 45% VO2peak at the start and the end of the sessions). SAP and DAP were applied from 15:30 till 19:30, exercise started at 18:00 and announced 20 minutes earlier to the AP systems. During SAP as compared to DAP: exercise-induced hypoglycemia (plasma glucose ≤3.3 mmol/L with symptoms or <3 regardless of symptoms) was observed in 31.25% (10/32) vs. 9% (3/33) of interventions (p=0.02); the median (IQR) percentage of time with glucose <4.0 mmol/L was 11 (0 to 46.7)% vs. 0 (0 to 0)% (p=0.0001); time with glucose between 4 and 10 mmol/L was 71.4 (53.2 to 100)% vs. 100 (100 to 100)% (p=0.003); the median area under the curve for glucose <4.0 mmol/L was 31.6 (0 to 153.9 vs. 0 (0 to 0) mmol/L×min per h (p=0.0001). Higher doses of glucagon were needed during the continuous exercise 14.4 (9.5 to 16.9) mg vs. the interval exercise sessions 8.5 (4.6 to 16.9) mg (p=0.03). In summary, DAP is offering a tighter control and a better potential to prevent hypoglycemia during exercise in adults with T1D."><meta property="og:image" content="https://aemami.ca/media/icon_hu29bb0f8250f761abddc65535b755b381_104744_512x512_fill_lanczos_center_3.png"><meta property="twitter:image" content="https://aemami.ca/media/icon_hu29bb0f8250f761abddc65535b755b381_104744_512x512_fill_lanczos_center_3.png"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2024-06-28T23:12:02+00:00"><meta property="article:modified_time" content="2024-06-29T23:32:00-04:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://aemami.ca/publication/taleb-2015-efficacy/"},"headline":"The efficacy of single-and dual-hormone artificial pancreas systems at regulating glucose levels during continuous and interval exercise in type 1 diabetes","datePublished":"2024-06-28T23:12:02Z","dateModified":"2024-06-29T23:32:00-04:00","author":{"@type":"Person","name":"Nadine Taleb"},"publisher":{"@type":"Organization","name":"Brock University","logo":{"@type":"ImageObject","url":"https://aemami.ca/media/icon_hu29bb0f8250f761abddc65535b755b381_104744_192x192_fill_lanczos_center_3.png"}},"description":"The artificial pancreas (AP) in its 2 versions, single-hormone AP (insulin only; SAP) and dual-hormone AP (insulin and glucagon; DAP), is a promising modality for the treatment of type 1 diabetes (T1D). We conducted an open-label, randomized, crossover study comparing SAP and DAP in 17 adults (age of 37.2±13.6 years, HBA1c 8.0±1.0%, during 2 types of exercises reported to have different hypoglycemic risks: moderate-intensity continuous exercise (60% VO2peak for 60 min) and high-intensity interval exercise (2 min alternating intervals at 85% and 50% VO2peak for 40 min, with 2×10 min at 45% VO2peak at the start and the end of the sessions). SAP and DAP were applied from 15:30 till 19:30, exercise started at 18:00 and announced 20 minutes earlier to the AP systems. During SAP as compared to DAP: exercise-induced hypoglycemia (plasma glucose ≤3.3 mmol/L with symptoms or \u003c3 regardless of symptoms) was observed in 31.25% (10/32) vs. 9% (3/33) of interventions (p=0.02); the median (IQR) percentage of time with glucose \u003c4.0 mmol/L was 11 (0 to 46.7)% vs. 0 (0 to 0)% (p=0.0001); time with glucose between 4 and 10 mmol/L was 71.4 (53.2 to 100)% vs. 100 (100 to 100)% (p=0.003); the median area under the curve for glucose \u003c4.0 mmol/L was 31.6 (0 to 153.9 vs. 0 (0 to 0) mmol/L×min per h (p=0.0001). Higher doses of glucagon were needed during the continuous exercise 14.4 (9.5 to 16.9) mg vs. the interval exercise sessions 8.5 (4.6 to 16.9) mg (p=0.03). In summary, DAP is offering a tighter control and a better potential to prevent hypoglycemia during exercise in adults with T1D."}</script><title>The efficacy of single-and dual-hormone artificial pancreas systems at regulating glucose levels during continuous and interval exercise in type 1 diabetes | Ali Emami</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=page-wrapper data-wc-page-id=3839c43a464bc75bad5267be183f7352><script src=../../js/wowchemy-init.min.6619cc29fe1a874b6ea1a0359aab5cfb.js></script><aside class=search-modal id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=# aria-label=Close><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search class=form-control aria-label=Search...></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><div class=page-header><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container-xl><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=../../>Ali Emami</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar-content aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=../../>Ali Emami</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=../../#about><span>Home</span></a></li><li class=nav-item><a class=nav-link href=../../news/newslist><span>News</span></a></li><li class=nav-item><a class=nav-link href=../../lab/lablist><span>Lab</span></a></li><li class=nav-item><a class="nav-link active" href=../../publication><span>Publications</span></a></li><li class=nav-item><a class=nav-link href=../../teaching/teachinglist><span>Courses</span></a></li><li class=nav-item><a class=nav-link href=../../service/servicelist><span>Services</span></a></li><li class=nav-item><a class=nav-link href=../../talk/talklist><span>Talks</span></a></li><li class=nav-item><a class=nav-link href=../../award/awardlist><span>Awards</span></a></li><li class=nav-item><a class=nav-link href=../../#contact><span>Contact</span></a></li><li class=nav-item><a class=nav-link href=../../uploads/resume.pdf><span>CV</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=# aria-label=Search><i class="fas fa-search" aria-hidden=true></i></a></li><li class="nav-item dropdown theme-dropdown"><a href=# class=nav-link data-toggle=dropdown aria-haspopup=true aria-label="Display preferences"><i class="fas fa-moon" aria-hidden=true></i></a><div class=dropdown-menu><a href=# class="dropdown-item js-set-theme-light"><span>Light</span></a>
<a href=# class="dropdown-item js-set-theme-dark"><span>Dark</span></a>
<a href=# class="dropdown-item js-set-theme-auto"><span>Automatic</span></a></div></li></ul></div></nav></div><div class=page-body><div class=pub><div class="article-container pt-3"><h1>The efficacy of single-and dual-hormone artificial pancreas systems at regulating glucose levels during continuous and interval exercise in type 1 diabetes</h1><div class=article-metadata><div><span>Nadine Taleb</span>, <span>Ahmad Haidar</span>, <span>Corinne Suppere</span>, <span>Ali Emami</span>, <span>Virginie Messier</span>, <span>Laurent Legault</span>, <span>Jean-Louise Chiasson</span>, <span>Remi Rabasa-Lhoret</span></div><span class=article-date>January 2015</span></div><div class="btn-links mb-3"><a href=# class="btn btn-outline-primary btn-page-header js-cite-modal" data-filename=/publication/taleb-2015-efficacy/cite.bib>Cite</a>
<a class="btn btn-outline-primary btn-page-header" href=https://www.canadianjournalofdiabetes.com/article/S1499-2671%2816%2930312-4/abstract target=_blank rel=noopener>CJD</a></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>The artificial pancreas (AP) in its 2 versions, single-hormone AP (insulin only; SAP) and dual-hormone AP (insulin and glucagon; DAP), is a promising modality for the treatment of type 1 diabetes (T1D). We conducted an open-label, randomized, crossover study comparing SAP and DAP in 17 adults (age of 37.2±13.6 years, HBA1c 8.0±1.0%, during 2 types of exercises reported to have different hypoglycemic risks: moderate-intensity continuous exercise (60% VO2peak for 60 min) and high-intensity interval exercise (2 min alternating intervals at 85% and 50% VO2peak for 40 min, with 2×10 min at 45% VO2peak at the start and the end of the sessions). SAP and DAP were applied from 15:30 till 19:30, exercise started at 18:00 and announced 20 minutes earlier to the AP systems. During SAP as compared to DAP: exercise-induced hypoglycemia (plasma glucose ≤3.3 mmol/L with symptoms or &lt;3 regardless of symptoms) was observed in 31.25% (10/32) vs. 9% (3/33) of interventions (p=0.02); the median (IQR) percentage of time with glucose &lt;4.0 mmol/L was 11 (0 to 46.7)% vs. 0 (0 to 0)% (p=0.0001); time with glucose between 4 and 10 mmol/L was 71.4 (53.2 to 100)% vs. 100 (100 to 100)% (p=0.003); the median area under the curve for glucose &lt;4.0 mmol/L was 31.6 (0 to 153.9 vs. 0 (0 to 0) mmol/L×min per h (p=0.0001). Higher doses of glucagon were needed during the continuous exercise 14.4 (9.5 to 16.9) mg vs. the interval exercise sessions 8.5 (4.6 to 16.9) mg (p=0.03). In summary, DAP is offering a tighter control and a better potential to prevent hypoglycemia during exercise in adults with T1D.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=../../publication/#1>Conference paper</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9"><em>Canadian Journal of Diabetes</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=share-box><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https://aemami.ca/publication/taleb-2015-efficacy/&amp;text=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes" target=_blank rel=noopener class=share-btn-twitter aria-label=twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https://aemami.ca/publication/taleb-2015-efficacy/&amp;t=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes" target=_blank rel=noopener class=share-btn-facebook aria-label=facebook><i class="fab fa-facebook"></i></a></li><li><a href="mailto:?subject=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes&amp;body=https://aemami.ca/publication/taleb-2015-efficacy/" target=_blank rel=noopener class=share-btn-email aria-label=envelope><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https://aemami.ca/publication/taleb-2015-efficacy/&amp;title=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes" target=_blank rel=noopener class=share-btn-linkedin aria-label=linkedin-in><i class="fab fa-linkedin-in"></i></a></li><li><a href="whatsapp://send?text=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes%20https://aemami.ca/publication/taleb-2015-efficacy/" target=_blank rel=noopener class=share-btn-whatsapp aria-label=whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https://aemami.ca/publication/taleb-2015-efficacy/&amp;title=The%20efficacy%20of%20single-and%20dual-hormone%20artificial%20pancreas%20systems%20at%20regulating%20glucose%20levels%20during%20continuous%20and%20interval%20exercise%20in%20type%201%20diabetes" target=_blank rel=noopener class=share-btn-weibo aria-label=weibo><i class="fab fa-weibo"></i></a></li></ul></div></div></div></div><div class=page-footer><div class=container><footer class=site-footer><p class=powered-by><a href=../../terms/></a></p><p class=powered-by>© 2024 Ali Emami</p><p class=powered-by>Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target=_blank rel=noopener>Wowchemy</a> — the free, <a href=https://github.com/wowchemy/wowchemy-hugo-themes target=_blank rel=noopener>open source</a> website builder that empowers creators.</p></footer></div></div><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code class="tex hljs"></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Download</a><div id=modal-error></div></div></div></div></div><script src=../../js/vendor-bundle.min.5a3a4e7cbc7b4e121b2d29312cf8ad59.js></script>
<script src=https://cdn.jsdelivr.net/gh/desandro/imagesloaded@v4.1.4/imagesloaded.pkgd.min.js integrity="sha512-S5PZ9GxJZO16tT9r3WJp/Safn31eu8uWrzglMahDT4dsmgqWonRY9grk3j+3tfuPr9WJNsfooOR7Gi7HL5W2jw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/metafizzy/isotope@v3.0.6/dist/isotope.pkgd.min.js integrity="sha512-Zq2BOxyhvnRFXu0+WE6ojpZLOU2jdnqbrM1hmVdGzyeCa1DgM3X5Q4A/Is9xA1IkbUeDd7755dNNI/PzSf2Pew==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/highlight.min.js integrity="sha512-Ypjm0o7jOxAd4hpdoppSEN0TQOC19UtPAqD+4s5AlXmUvbmmS/YMxYqAqarQYyxTnB6/rqip9qcxlNB/3U9Wdg==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/bash.min.js crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/cpp.min.js crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/julia.min.js crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.2.1/build/languages/python.min.js crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/leaflet@1.7.1/dist/leaflet.min.js integrity crossorigin=anonymous></script>
<script id=search-hit-fuse-template type=text/x-template>
        <div class="search-hit" id="summary-{{key}}">
          <div class="search-hit-content">
            <div class="search-hit-name">
              <a href="{{relpermalink}}">{{title}}</a>
              <div class="article-metadata search-hit-type">{{type}}</div>
              <p class="search-hit-description">{{snippet}}</p>
            </div>
          </div>
        </div>
      </script><script src=https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin=anonymous></script>
<script src=../../en/js/wowchemy.min.44f54723226744971bcdd9c0ca685057.js></script></body></html>